News
2024.05.24
DXVX has demonstrated efficacy in preclinical results of its independently designed and synthesized mRNA anticancer vaccine. On the 24th, DXVX announced that its independently designed and synthesized mRNA anticancer vaccine candidate demonstrated anticancer effects in preclinical stages. In this preclinical cell line test, it exhibited superior expression efficacy and remarkable anticancer effects compared to linear mRNA. The company has been synthesizing candidate materials for preclinical trials of cancer vaccines using NewClicsBio's mRNA technology and collaborating with the Pohang University of Science and Technology's Industry-Academia Cooperation Foundation to utilize the production process technology of lipid nanoparticles (LNPs) for delivery. DXVX's mRNA cancer vaccine candidate targets melanoma as its primary indication and is under development for indications across various cancer types such as breast cancer. The company is planning to proceed to the next stage, which is animal testing. The company plans to prepare material patent applications and academic presentations on OVM-200, a recombinant overlapping peptide (ROP)-based cancer vaccine scheduled for introduction later this year, focusing on the results of the recent mRNA preclinical studies, as well as on-going research and development (R&D) efforts on the pipeline. A DXVX representative stated, "We are currently expanding collaborations with leading domestic and international academic and research institutions," adding, "We are also considering parallel licensing out to accelerate pipeline development and early commercialization."